AtCor Medical (AMDHF.PK), the developer and marketer of SphygmoCor systems, which non-invasively measures central aortic blood pressure and arterial stiffness, announced that it had received 510k marketing clearance from the US Food and Drug Administration or FDA for its SphygmoCor XCEL device.
Commenting on SphygmoCor XCEL, the company stated that it is a new blood pressure cuff- based system that allows brachial and central aortic blood pressure to be measured quickly and simply.
AtCor also said that with the new system, traditional brachial blood pressure measurement and pulse wave analysis, which measures central aortic pressure, can be performed quickly and easily.
The SphygmoCor XCEL system also provides a simpler and more convenient method of performing pulse wave velocity measurement, a test used to measure aortic stiffness, AtCor added.
Click here to receive FREE breaking news email alerts for Atcor Medical Holding and others in your portfolio
by RTT Staff Writer
For comments and feedback: editorial@rttnews.com